Note I - Equity-based Compensation - Stock Options, SARs and RSUs Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended
		Jun. 30, 2018		Mar. 31, 2018
Outstanding (in shares)		2,211
Outstanding, weighted average exercise price (in dollars per share)		$ 4.39
Outstanding, weighted average remaining contractual term (Year)	[1]	4 years 248 days	[2]	4 years 317 days
Outstanding, aggregate value	[3]	$ 16,694	[2]	$ 16,502
Options granted (in shares)		6
Options granted, weighted average exercise price (in dollars per share)		$ 11.75
Options / SARs / RSUs cancelled/forfeited/expired (in shares)		(15)
Options / SARs / RSUs cancelled/forfeited/expired, weighted average exercise price (in dollars per share)		$ 3.77
Options / SARs exercised and RSUs vested (in shares)		(117)
Options / SARs exercised and RSUs vested, weighted average exercise price (in dollars per share)		$ 2.56
Outstanding (in shares)		2,107	[2]	2,211
Outstanding, weighted average exercise price (in dollars per share)		$ 4.55	[2]	$ 4.39
Exercisable (in shares)	[4]	801
Exercisable, weighted average exercise price (in dollars per share)	[4]	$ 8.78
Exercisable, weighted average remaining contractual term (Year)	[1],[4]	4 years 62 days
Exercisable, aggregate value	[3],[4]	$ 2,964
Stock Appreciation Rights (SARs) [Member]
Non-option instruments granted (in shares)		13
Non-option instruments, weighted average exercise price (in dollars per share)		$ 12.50
Restricted Stock Units (RSUs) [Member]
Non-option instruments granted (in shares)		9
Non-option instruments, weighted average exercise price (in dollars per share)

[1] Calculation of weighted average remaining contractual term does not include RSUs that were granted, which have indefinite contractual term.

[2] Due to the ceiling imposed on the SAR grants, the outstanding amount above can be exercised for a maximum of 2,013 shares of the Company's common stock as of June 30, 2018. SAR grants made on or after January 1, 2012 are convertible for a maximum number of shares of the Company's common stock equal to 50% of the SARs subject to the grant.

[3] Calculation of aggregate intrinsic value is based on the share price of the Company's common stock on June 30, 2018 ($12.45 per share).

[4] Due to the ceiling imposed on the SAR grants, the exercisable amount above can be exercised for a maximum of 774 shares of the Company's common stock as of June 30, 2018.